← Eichor
Condition: Lymphoma Non Hodgkin Nhl Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Lymphoma Non Hodgkin Nhl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Re
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07225985Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT07312630Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06589089Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Phase N/A · 2 location(s) · Emory University · NCT03501576Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
Phase 1/Phase 2 · 1 location(s) · Fondazione Matilde Tettamanti Menotti De Marchi Onlus · NCT05869279A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
Phase N/A · 3 location(s) · Henry M. Jackson Foundation for the Advancement of Military · NCT07652580Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)
Phase N/A · 1 location(s) · Czech Lymphoma Study Group · NCT03199066A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants
Phase 1/Phase 2 · 30 location(s) · Hoffmann-La Roche · NCT05533775Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839456A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Phase 4 · 38 location(s) · Eli Lilly and Company · NCT06876649Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Phase 2 · 104 location(s) · SWOG Cancer Research Network · NCT05890352Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
Phase 1/Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06838832Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 · 3 location(s) · SIRPant Immunotherapeutics, Inc. · NCT05967416A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT07020533The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
NA · 2 location(s) · Mayo Clinic · NCT05876923Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07195799A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Phase 1/Phase 2 · 6 location(s) · Daiichi Sankyo · NCT07220616A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · Aibin Liang，MD，Ph.D. · NCT06734871A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06446128B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide
Phase 1 · 1 location(s) · Mayo Clinic · NCT06191887A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 12 location(s) · Enterome · NCT04669171A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgki
Phase 1 · 16 location(s) · Sanofi · NCT06392477Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06013423Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
Phase 2 · 1 location(s) · Koo Foundation Sun Yat-Sen Cancer Center · NCT06461182Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · 39 location(s) · CellCentric Ltd. · NCT04068597Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 2 location(s) · Samsung Medical Center · NCT06552559IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05365659A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1/Phase 2 · 3 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05623982
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.